EYPT EyePoint, Inc. - Common Stock
关于 EyePoint, Inc. - Common Stock 公司概况(来自维基百科)
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
阅读更多
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ). QinetiQ continues to be a strategic partner.
In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.
来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
EYPT 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
EYPT 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
EYPT 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 7 35.0%
- 买入 12 60.0%
- 持有 1 5.0%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
13 位分析师 · 2026-08-19收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-1.09 | $-0.97 | -0.12% |
| 2026年3月31日 | $-0.99 | $-0.82 | -0.17% |
| 2025年12月31日 | $-0.81 | $-0.76 | -0.05% |
| 2025年9月30日 | $-0.85 | $-0.80 | -0.05% |
| 2025年6月30日 | $-0.85 | $-0.81 | -0.04% |
| 2025年3月31日 | $-0.65 | $-0.67 | 0.02% |
同行比较(GICS 子行业) 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| EYPT | $1.51B | -5.8 | -27.5% | -739.4% | -84.0% | — |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | — |
| CTNM | — | -5.3 | — | — | -27.7% | — |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | — |
| EOLS | $432M | -8.3 | 11.6% | -17.4% | 247.3% | 66.3% |
| RLMD | $354M | -3.3 | 93.7% | — | -112.0% | — |
| BIOA | $495M | -5.9 | — | -896.1% | -28.4% | — |
| AVIR | $279M | -1.8 | — | — | -49.5% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 16
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31M | $43M | $46M | $41M | $37M | $34M | $20M | $5M | $8M | $2M | $27M | |
| R&D Expense | $221M | $133M | $65M | $50M | $28M | $17M | $15M | $19M | $15M | $14M | $12M | |
| SG&A Expense | $52M | $52M | $40M | $35M | $26M | $21M | $18M | $15M | $11M | $9M | $8M | |
| Operating Expenses | $275M | $189M | $121M | $141M | $92M | $72M | $68M | $44M | $26M | $23M | $20M | |
| Operating Income | $-243M | $-146M | $-75M | $-100M | $-55M | $-37M | $-48M | $-39M | $-19M | $-22M | $6M | |
| Interest Expense | · | · | $1M | $3M | $5M | $7M | $6M | $2M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | $19.0K | |
| Other Non-op | $12M | $15M | $7M | $2M | $292.0K | $58.0K | $1M | $420.0K | $91.0K | $72.0K | $22.0K | |
| Pretax Income | $-232M | $-131M | $-71M | $-102M | $-58M | $-45M | $-57M | · | $-18M | $-22M | $6M | |
| Income Tax | $279.0K | $90.0K | $83.0K | · | $0 | $0 | $0 | · | $0 | $-155.0K | $96.0K | |
| Net Income | $-232M | $-131M | $-71M | $-102M | $-58M | $-45M | $-57M | $-86M | $-18M | $-22M | $6M | |
| EPS (Basic) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 | · | · | · | $-0.52 | $-0.68 | $0.22 | |
| EPS (Diluted) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 | · | · | · | $-0.52 | $-0.68 | $0.21 | |
| Shares (Basic) | 73,251 | 56,298 | 38,904 | 37,317,000 | 28,758,000 | · | · | · | 35,343,765 | 31,623,473 | 29,378,250 | |
| Shares (Diluted) | 73,251 | 56,298 | 38,904 | 37,317,000 | 28,758,000 | · | · | · | 35,343,765 | 31,623,473 | 30,584,140 | |
| EBITDA | $-241M | $-146M | $-75M | $-100M | $-55M | · | $-48M | · | · | $-22M | $6M |
资产负债表 27
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $100M | $281M | $96M | $179M | $45M | $22M | $45M | $17M | $15M | $19M | |
| Short-term Investments | $204M | $271M | $50M | $49M | $33M | $0 | $0 | $0 | $0 | $14M | $9M | |
| Inventory | $2M | $2M | $4M | $3M | $4M | $5M | $2M | $279.0K | · | · | · | |
| Prepaid Expense | $20M | $9M | $9M | $10M | $4M | $3M | $6M | $1M | $591.0K | $483.0K | $681.0K | |
| Other Current Assets | $2M | $1M | $1M | $782.0K | $517.0K | · | · | · | · | · | · | |
| Current Assets | $329M | $383M | $345M | $173M | $238M | $63M | $42M | $48M | $18M | $30M | $30M | |
| PP&E (Net) | $9M | $8M | $5M | $1M | $476.0K | $630.0K | $357.0K | $288.0K | $313.0K | $290.0K | $338.0K | |
| PP&E (Gross) | $15M | $12M | $8M | $3M | $2M | $2M | $1M | $983.0K | $799.0K | $2M | $2M | |
| Accum. Depreciation | $6M | $4M | $3M | $2M | $1M | $1M | $839.0K | $695.0K | $486.0K | $2M | $2M | |
| Intangibles | · | · | · | $0 | $23M | $25M | $28M | $30M | $364.0K | $1M | $2M | |
| Other Non-current Assets | $6M | $6M | $0 | · | · | · | · | · | · | · | · | |
| Total Assets | $364M | $418M | $355M | $180M | $263M | $92M | $73M | $78M | $19M | $32M | $32M | |
| Accounts Payable | $10M | $12M | $7M | $6M | $7M | $5M | $4M | $3M | $1M | $1M | $744.0K | |
| Accrued Liabilities | $24M | $18M | $18M | $16M | $14M | $8M | $7M | $4M | $4M | $4M | $3M | |
| Short-term Debt | · | · | $0 | $10M | $0 | · | · | · | · | · | · | |
| Current Liabilities | $37M | $49M | $63M | $35M | $24M | $15M | $12M | $21M | $5M | $5M | $3M | |
| Capital Leases | $21M | $22M | $5M | $6M | $2M | $2M | $3M | $0 | · | · | · | |
| Other Non-current Liabilities | $87.0K | $205.0K | $0 | $600.0K | $2M | $2M | $3M | $1M | $51.0K | · | · | |
| Total Liabilities | $58M | $82M | $89M | $84M | $79M | $73M | $65M | $41M | $5M | $11M | $9M | |
| Long-term Debt | · | · | · | $30M | · | · | · | · | · | · | · | |
| Total Debt | · | · | $0 | $40M | $37M | · | $47M | · | · | · | · | |
| Common Stock | $83.0K | $68.0K | $49.0K | $34.0K | $34.0K | $18.0K | $11.0K | $95.0K | $39.0K | $34.0K | $29.0K | |
| Retained Earnings | $-1.10B | $-873M | $-742M | $-671M | $-569M | $-511M | $-465M | $-408M | $-311M | $-292M | $-271M | |
| AOCI | $961.0K | $1M | $864.0K | $786.0K | $841.0K | $841.0K | $840.0K | $839.0K | $833.0K | $852.0K | $945.0K | |
| Stockholders' Equity | $306M | $337M | $266M | $96M | $184M | $19M | $8M | $38M | $13M | $21M | $23M | |
| Liabilities + Equity | $364M | $418M | $355M | $180M | $263M | $92M | $73M | $78M | $19M | $32M | $32M | |
| Shares Outstanding | 82,826,416 | 68,266,005 | 49,043,074 | 34,082,934 | 33,905,826 | 18,139,981 | 10,941,659 | 95,372,236 | 39,356,999 | 34,172,919 | 29,412,365 |
现金流 18
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $464.0K | · | · | · | · | · | · | · | · | |
| Stock-based Comp | $28M | $37M | $12M | $14M | $7M | $6M | $5M | · | $2M | $2M | $2M | |
| Deferred Tax | $279.0K | $90.0K | $83.0K | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | · | · | $0 | $2M | $2M | $2M | $2M | $981.0K | $724.0K | $756.0K | $770.0K | |
| Restructuring | · | · | · | · | · | $590.0K | · | · | $472.0K | · | · | |
| Other Non-cash | $-39M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-240M | $-126M | $2M | $-65M | $-50M | $-14M | $-57M | · | $-20M | $-16M | $10M | |
| CapEx | $3M | $4M | $3M | $2M | $156.0K | $362.0K | $213.0K | · | $147.0K | $113.0K | $161.0K | |
| Investing Cash Flow | $69M | $-219M | $-3M | $-17M | $-33M | $-362.0K | $-213.0K | · | $14M | $-4M | · | |
| Debt Issued | · | · | $0 | $30M | $0 | · | $50M | · | $0 | $0 | · | |
| Net Debt Issued | · | $0 | $-30M | $-8M | $0 | · | $30M | · | · | · | · | |
| Stock Issued | $173M | $163M | $226M | $0 | · | $50M | $23M | · | $8M | $16M | $0 | |
| Net Stock Activity | $173M | $163M | $226M | · | · | · | $23M | · | · | $16M | · | |
| Financing Cash Flow | $174M | $164M | $187M | $-690.0K | $217M | $37M | $34M | · | $9M | $17M | · | |
| Net Change in Cash | $2M | $-182M | $186M | $-83M | $134M | $23M | $-23M | · | $2M | $-4M | $4M | |
| Taxes Paid | $200.0K | $100.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-243M | $-130M | $-2M | $-67M | $-50M | · | $-57M | · | · | $-16M | $10M | |
| Levered FCF | · | · | $-3M | $-70M | $-56M | · | $-63M | · | · | · | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | · | -235.0% | · | · | -1344.1% | 24.2% | |
| Net Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | · | -278.9% | · | · | -1330.1% | 23.9% | |
| Pretax Margin | -738.5% | -302.2% | -153.7% | -247.0% | -158.1% | · | -278.9% | · | · | -1339.6% | 24.2% | |
| EBITDA Margin | -768.6% | -337.1% | -163.1% | -240.6% | -149.6% | · | -235.0% | · | · | -1344.1% | 24.2% | |
| ROA | -59.3% | -33.8% | -26.4% | -46.1% | -32.9% | · | -75.1% | · | · | -67.3% | 23.1% | |
| ROE | -84.0% | -47.1% | -43.6% | -87.9% | -42.2% | · | -468.1% | · | · | -90.8% | 24.8% | |
| ROIC | -79.6% | -43.4% | -28.2% | -73.2% | -25.0% | · | -86.2% | · | · | -103.5% | 27.1% |
流动性与偿付能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.9 | 7.8 | 5.5 | 5.0 | 10.0 | · | 3.6 | · | · | 5.9 | 8.9 | |
| Quick Ratio | 8.3 | 7.6 | 5.2 | 4.2 | 8.9 | · | 1.9 | · | · | 5.7 | 8.5 | |
| Debt / Equity | · | · | 0.0 | 0.4 | 0.2 | · | 5.7 | · | · | · | · | |
| LT Debt / Equity | · | · | · | 0.3 | 0.2 | · | 5.7 | · | · | · | · | |
| Interest Coverage | · | · | -60.2 | -31.2 | -10.1 | · | -7.7 | · | · | · | · |
效率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | · | 0.1 | 1.0 |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -27.5% | -6.0% | 11.1% | 12.1% | 7.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -8.8% | 5.4% | 10.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $31M | $43M | $46M | $41M | $37M | $34M | $20M | · | $8M | $2M | $27M | |
| Net Income TTM | $-232M | $-131M | $-71M | $-102M | $-58M | $-45M | $-57M | · | $-18M | $-22M | $6M | |
| Market Cap | $1.51B | $509M | $1.13B | $119M | $415M | · | $1.70B | · | · | $967M | $1.11B | |
| Enterprise Value | · | · | $802M | $15M | $240M | · | $1.72B | · | · | · | · | |
| P/E | -5.8 | -3.2 | -12.7 | -1.3 | -6.0 | -9.8 | -23.1 | · | -32.9 | -41.6 | 179.5 | |
| P/S | 48.2 | 11.8 | 24.6 | 2.9 | 11.2 | · | 83.3 | · | · | 597.0 | 41.7 | |
| P/B | 4.9 | 1.5 | 4.3 | 1.2 | 2.3 | · | 203.6 | · | · | 46.3 | 47.5 | |
| P / Tangible Book | 4.9 | 1.5 | 4.3 | 1.2 | 2.6 | · | · | · | · | · | · | |
| P / Cash Flow | -6.3 | -4.0 | 604.5 | -1.8 | -8.3 | · | -29.9 | · | · | -59.3 | 107.7 | |
| P / FCF | -6.2 | -3.9 | -704.8 | -1.8 | -8.3 | · | -29.8 | · | · | -58.9 | 109.4 | |
| EV / EBITDA | · | · | -10.7 | -0.1 | -4.3 | · | -36.0 | · | · | · | · | |
| EV / FCF | · | · | -499.0 | -0.2 | -4.8 | · | -30.2 | · | · | · | · | |
| EV / Revenue | · | · | 17.4 | 0.4 | 6.5 | · | 84.5 | · | · | · | · | |
| Earnings Yield | -17.3% | -31.1% | -7.9% | -78.3% | -16.6% | -10.2% | -4.3% | · | -3.0% | -2.4% | 0.56% |
损益表 16
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $507.0K | $696.0K | $619.0K | $966.0K | $5M | $24M | $12M | $11M | $9M | $12M | $14M | $15M | $9M | $8M | $11M | $10M | |
| Cost of Revenue | · | · | · | · | · | · | · | $736.0K | $1M | $759.0K | · | $1M | $2M | $640.0K | · | · | |
| R&D Expense | $84M | $72M | $59M | $48M | $55M | $59M | $43M | $30M | $30M | $30M | $18M | $17M | $16M | $14M | $16M | $11M | |
| SG&A Expense | $14M | $15M | $11M | $14M | $12M | $14M | $13M | $13M | $13M | $14M | $11M | $11M | $9M | $9M | $8M | $9M | |
| Operating Expenses | $98M | $88M | $71M | $63M | $68M | $73M | $57M | $43M | $44M | $45M | $30M | $30M | $32M | $29M | $54M | $28M | |
| Operating Income | $-97M | $-87M | $-70M | $-62M | $-62M | $-49M | $-45M | $-33M | $-35M | $-33M | $-16M | $-14M | $-23M | $-22M | $-44M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $0 | $0 | · | $0 | $435.0K | $812.0K | $781.0K | $662.0K | |
| Other Non-op | $3M | $2M | $3M | $2M | $3M | $4M | $4M | $3M | $4M | $4M | $2M | $2M | $2M | $1M | $1M | $640.0K | |
| Pretax Income | $-94M | · | $-67M | $-60M | $-59M | · | $-41M | $-29M | $-31M | · | · | · | · | · | · | · | |
| Income Tax | $0 | $-50.0K | $186.0K | $0 | $93.0K | $0 | $90.0K | $0 | $0 | · | · | · | · | · | · | · | |
| Net Income | $-94M | $-85M | $-68M | $-60M | $-59M | $-45M | $-41M | $-29M | $-31M | $-29M | $-14M | $-13M | $-23M | $-21M | $-43M | $-18M | |
| EPS (Basic) | $-1.09 | $-0.99 | $-0.82 | $-0.85 | $-0.85 | $-0.65 | $-0.65 | $-0.54 | $-0.58 | $-0.55 | $-0.32 | $-0.33 | $-0.61 | $-0.56 | $-1.17 | $-0.49 | |
| EPS (Diluted) | $-1.09 | $-0.99 | $-0.82 | $-0.85 | $-0.85 | $-0.65 | $-0.65 | $-0.54 | $-0.58 | $-0.55 | $-0.32 | $-0.33 | $-0.61 | $-0.56 | $-1.17 | $-0.49 | |
| Shares (Basic) | 86,543 | 85,999 | -69,833,843 | 70,168 | 69,926 | 69,767 | -52,964,357 | 54,449 | 53,206 | 52,913,000 | -75,915,582 | 38,341,000 | 37,576,000 | 37,486 | -74,596,000 | 37,338,000 | |
| Shares (Diluted) | 86,543 | 85,999 | -69,833,843 | 70,168 | 69,926 | 69,767 | -52,964,357 | 54,449 | 53,206 | 52,913,000 | -75,915,582 | 38,341,000 | 37,576,000 | 37,486 | -74,596,000 | 37,338,000 | |
| EBITDA | $-97M | $-87M | · | $-62M | $-62M | $-49M | · | $-33M | $-35M | $-33M | · | $-14M | $-23M | $-22M | · | $-18M |
资产负债表 27
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110M | $78M | $102M | $75M | $71M | $85M | $100M | $80M | $91M | $271M | $281M | $133M | $140M | $106M | $96M | $75M | |
| Short-term Investments | $70M | $145M | $204M | $129M | $185M | $233M | $271M | $174M | $189M | $28M | $50M | $3M | $3M | $17M | $49M | $82M | |
| Inventory | $2M | $1M | $2M | $2M | $3M | $2M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $4M | $3M | $4M | |
| Prepaid Expense | $6M | $25M | $20M | $9M | $6M | $6M | $9M | $12M | $10M | $11M | $9M | $9M | $9M | $9M | $10M | $10M | |
| Other Current Assets | $987.0K | $1M | $2M | $899.0K | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $549.0K | $0 | $0 | $782.0K | · | |
| Current Assets | $189M | $250M | $329M | $216M | $265M | $327M | $383M | $269M | $295M | $318M | $345M | $150M | $167M | $146M | $173M | $192M | |
| PP&E (Net) | $10M | $9M | $9M | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $5M | $4M | $3M | $3M | $1M | $1M | |
| PP&E (Gross) | · | · | $15M | · | · | · | $12M | · | · | · | $8M | · | · | · | $3M | · | |
| Accum. Depreciation | · | · | $6M | · | · | · | $4M | · | · | · | $3M | · | · | · | $2M | · | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $21M | |
| Other Non-current Assets | $9M | $9M | $6M | $6M | $6M | $6M | $6M | $2M | · | · | $0 | · | · | · | · | · | |
| Total Assets | $228M | $288M | $364M | $252M | $301M | $363M | $418M | $301M | $324M | $329M | $355M | $160M | $176M | $155M | $180M | $220M | |
| Accounts Payable | $17M | $19M | $10M | $10M | $20M | $16M | $12M | $7M | $14M | $7M | $7M | $10M | $11M | $9M | $6M | $6M | |
| Accrued Liabilities | $22M | $16M | $24M | $18M | $11M | $18M | $18M | $14M | $13M | $16M | $18M | $13M | $15M | $10M | $16M | $16M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $5M | $10M | $10M | |
| Current Liabilities | $42M | $37M | $37M | $30M | $33M | $42M | $49M | $49M | $62M | $63M | $63M | $64M | $69M | $27M | $35M | $34M | |
| Capital Leases | $20M | $20M | $21M | $21M | $22M | $22M | $22M | $22M | $22M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | |
| Other Non-current Liabilities | $23.0K | $55.0K | $87.0K | $118.0K | $148.0K | $177.0K | $205.0K | $233.0K | · | · | $0 | $0 | $0 | $600.0K | $600.0K | $600.0K | |
| Total Liabilities | $62M | $58M | $58M | $52M | $55M | $64M | $82M | $82M | $96M | $79M | $89M | $101M | $118M | $76M | $84M | $84M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $30M | · | $30M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $35M | · | $40M | |
| Common Stock | $85.0K | $83.0K | $83.0K | $70.0K | $69.0K | $69.0K | $68.0K | $53.0K | $52.0K | $50.0K | $49.0K | $35.0K | $34.0K | $34.0K | $34.0K | $34.0K | |
| Retained Earnings | $-1.28B | $-1.19B | $-1.10B | $-1.04B | $-978M | $-918M | $-873M | $-832M | $-802M | $-771M | $-742M | $-728M | $-715M | $-693M | $-671M | $-628M | |
| AOCI | $793.0K | $802.0K | $961.0K | $919.0K | $832.0K | $923.0K | $1M | $1M | $792.0K | $836.0K | $864.0K | $841.0K | $842.0K | $843.0K | $786.0K | $653.0K | |
| Stockholders' Equity | $166M | $230M | $306M | $200M | $246M | $298M | $337M | $219M | $228M | $250M | $266M | $59M | $57M | $78M | $96M | $136M | |
| Liabilities + Equity | $228M | $288M | $364M | $252M | $301M | $363M | $418M | $301M | $324M | $329M | $355M | $160M | $176M | $155M | $180M | $220M | |
| Shares Outstanding | 84,981,843 | 83,453,001 | 82,826,416 | 69,569,813 | 68,889,649 | 68,811,357 | 68,266,005 | 53,524,364 | 52,160,305 | 49,885,701 | 49,043,074 | 35,309,432 | 34,306,118 | 34,301,926 | 34,082,934 | 34,072,155 |
现金流 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $690.0K | $636.0K | $698.0K | $576.0K | $538.0K | $497.0K | $467.0K | $408.0K | $362.0K | $303.0K | $112.0K | · | · | · | · | · | |
| Stock-based Comp | $10M | $12M | $7M | $6M | $7M | $8M | $8M | $7M | $9M | $13M | $4M | $4M | $2M | $3M | $3M | $3M | |
| Deferred Tax | · | · | $369.0K | $0 | · | · | $90.0K | $0 | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $205.0K | $615.0K | |
| Other Non-cash | · | $-8M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-62M | $-81M | $-65M | $-59M | $-63M | $-53M | $-36M | $-39M | $-20M | $-31M | $-23M | $-15M | $57M | $-17M | $-13M | $-13M | |
| CapEx | $1M | $997.0K | $986.0K | $798.0K | $1M | $276.0K | $384.0K | $2M | $900.0K | $1M | $883.0K | $2M | $396.0K | $484.0K | $585.0K | $1M | |
| Investing Cash Flow | $75M | $59M | $-75M | $55M | $48M | $40M | $-96M | $16M | $-160M | $21M | $-47M | $-2M | $13M | $32M | $33M | $6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | · | · | $167M | $7M | · | · | $152M | · | · | · | $216M | · | · | · | $0 | · | |
| Financing Cash Flow | $20M | $-3M | $167M | $7M | $238.0K | $-951.0K | $152M | $12M | $329.0K | $115.0K | $218M | $10M | $-37M | $-5M | $-58.0K | $92.0K | |
| Net Change in Cash | $33M | $-24M | $27M | $3M | $-14M | $-15M | $20M | $-11M | $-180M | $-10M | $148M | $-7M | $34M | $10M | $20M | $-7M | |
| Free Cash Flow | · | $-82M | · | · | · | $-53M | · | · | · | $-32M | · | · | · | $-17M | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -19207.1% | -12532.5% | · | -6420.8% | -1166.8% | -199.7% | · | -311.2% | -364.5% | -285.2% | · | -94.7% | -250.0% | -280.5% | · | -183.8% | |
| Net Margin | -18633.1% | -12188.5% | · | -6183.4% | -1114.3% | -184.8% | · | -279.0% | -325.3% | -250.6% | · | -83.0% | -251.7% | -275.5% | · | -184.0% | |
| Pretax Margin | -18633.1% | · | · | -6183.4% | -1112.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -19207.1% | -12441.1% | · | -6420.8% | -1166.8% | -199.7% | · | -311.2% | -364.5% | -285.2% | · | -94.7% | -250.0% | -280.5% | · | -183.8% | |
| ROA | -35.7% | -26.1% | · | -21.6% | -19.0% | -13.1% | · | -12.7% | -12.3% | -12.1% | · | -6.6% | -11.2% | -10.6% | · | -9.5% | |
| ROE | -45.8% | -32.1% | · | -28.5% | -25.1% | -16.5% | · | -21.2% | -21.6% | -17.8% | · | -12.9% | -22.0% | -17.3% | · | -16.1% | |
| ROIC | -58.5% | · | · | -31.0% | -25.3% | · | · | · | · | · | · | · | · | · | · | · |
流动性与偿付能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.7 | · | 7.2 | 8.0 | 7.8 | · | 5.5 | 4.7 | 5.1 | · | 2.4 | 2.4 | 5.4 | · | 5.6 | |
| Quick Ratio | 4.3 | 5.9 | · | 6.8 | 7.7 | 7.6 | · | 5.2 | 4.5 | 4.8 | · | 2.1 | 2.1 | 4.5 | · | 4.6 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.4 | · | 0.3 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.4 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | · | -52.3 | -26.5 | · | -27.8 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.2 | 0.4 | 0.2 | · | · | · | · | · | · |
估值 (TTM) 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $31M | · | $41M | $50M | $56M | · | $47M | $45M | $44M | · | $42M | $38M | $39M | · | $40M | |
| Net Income TTM | $-298M | $-249M | · | $-194M | $-165M | $-135M | · | $-102M | $-96M | $-86M | · | $-75M | $-82M | $-80M | · | $-75M | |
| Market Cap | $1.22B | $1.08B | · | $991M | $648M | $373M | · | $428M | $454M | $1.03B | · | $282M | $298M | $101M | · | $270M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | $146M | $156M | $13M | · | $152M | |
| P/E | -3.8 | -3.9 | · | -4.9 | -3.6 | -2.3 | · | -4.0 | -4.2 | -10.1 | · | -4.0 | -4.0 | -1.4 | · | -3.7 | |
| P/S | 162.0 | 34.2 | · | 24.0 | 13.0 | 6.6 | · | 9.1 | 10.0 | 23.6 | · | 6.7 | 7.8 | 2.6 | · | 6.7 | |
| P/B | 7.3 | 4.7 | · | 4.9 | 2.6 | 1.2 | · | 2.0 | 2.0 | 4.1 | · | 4.8 | 5.2 | 1.3 | · | 2.0 | |
| P / Tangible Book | 7.3 | 4.7 | · | 4.9 | 2.6 | 1.2 | · | 2.0 | 2.0 | 4.1 | · | 4.8 | 5.2 | 1.3 | · | 2.3 | |
| P / Cash Flow | · | -13.4 | · | · | · | -7.0 | · | · | · | -33.1 | · | · | · | -6.0 | · | · | |
| P / FCF | · | -13.2 | · | · | · | -7.0 | · | · | · | -31.9 | · | · | · | -5.8 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | · | · | · | -10.1 | -6.9 | -0.6 | · | -8.3 | |
| EV / FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | -0.8 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | 3.5 | 4.1 | 0.3 | · | 3.8 | |
| Earnings Yield | -26.4% | -25.9% | · | -20.3% | -27.8% | -42.8% | · | -25.0% | -23.8% | -9.9% | · | -24.9% | -25.1% | -72.5% | · | -27.2% |
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $31M | $43M | $46M | $41M | $37M |
| 营业利润率 % | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% |
| 净收入 | $-232M | $-131M | $-71M | $-102M | $-58M |
| 稀释后每股收益 (EPS) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | — | — | 0.0 | 0.4 | 0.2 |
| 流动比率 | 8.9 | 7.8 | 5.5 | 5.0 | 10.0 |
| 速动比率 | 8.3 | 7.6 | 5.2 | 4.2 | 8.9 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-243M | $-130M | $-2M | $-67M | $-50M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存,并会跟随您浏览所有股票。
机构持有人 (13F) 217 家申报者 · $1.2B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 37 (-25 与上一季度对比) | 21 (-2 与上一季度对比) | 63 (-9 与上一季度对比) | 56 (+18 与上一季度对比) | +3.1M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | $118638163 | 8296375 | 10.19% | 股份 |
| Cormorant Asset Management, LP | $100100000 | 7000000 | 8.60% | 股份 |
| VANGUARD GROUP INC | $78353343 | 4288634 | 6.73% | 股份 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $69037426 | 4827792 | 5.93% | 股份 |
| Commodore Capital LP | $65780000 | 4600000 | 5.65% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $51912604 | 3630252 | 4.46% | 股份 |
| JANUS HENDERSON GROUP PLC | $45962750 | 3565768 | 3.95% | 股份 |
| Paradigm Biocapital Advisors LP | $41332677 | 2890397 | 3.55% | 股份 |
| STATE STREET CORP | $33712894 | 2357545 | 2.90% | 股份 |
| Aberdeen Group plc | $28725869 | 2008802 | 2.47% | 股份 |
| PERCEPTIVE ADVISORS LLC | $28600000 | 2000000 | 2.46% | 卖出期权 |
| Balyasny Asset Management L.P. | $25916719 | 1812358 | 2.23% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $25269659 | 1766745 | 2.17% | 股份 |
| CITADEL ADVISORS LLC | $25214389 | 1763244 | 2.17% | 股份 |
| Parkman Healthcare Partners LLC | $18420731 | 1288163 | 1.58% | 股份 |
| EVENTIDE ASSET MANAGEMENT, LLC | $17811837 | 1245583 | 1.53% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $16890345 | 1181143 | 1.45% | 股份 |
| Essex Woodlands Management, Inc. | $15513455 | 1084857 | 1.33% | 股份 |
| ORBIMED ADVISORS LLC | $15288802 | 1069147 | 1.31% | 股份 |
| 5AM Venture Management, LLC | $15015000 | 1050000 | 1.29% | 股份 |
| Rosalind Advisors, Inc. | $14131689 | 988230 | 1.21% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13885500 | 971014 | 1.19% | 股份 |
| HSBC HOLDINGS PLC | $11918407 | 833455 | 1.02% | 股份 |
| Candriam S.C.A. | $11254258 | 787769 | 0.97% | 股份 |
| AMERIPRISE FINANCIAL INC | $11087640 | 775357 | 0.95% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $11062981 | 773635 | 0.95% | 股份 |
| Artia Global Partners LP | $10969501 | 767098 | 0.94% | 股份 |
| Blue Owl Capital Holdings LP | $10905094 | 762594 | 0.94% | 股份 |
| Patient Square Capital LP | $10296000 | 720000 | 0.88% | 股份 |
| Principia Wealth Advisory, LLC | $9696346 | 530725 | 0.83% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9260866 | 647613 | 0.80% | 股份 |
| Sio Capital Management, LLC | $8910759 | 623130 | 0.77% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $7996789 | 559216 | 0.69% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7899320 | 552400 | 0.68% | 买入期权 |
| Alyeska Investment Group, L.P. | $7284463 | 509403 | 0.63% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $7151330 | 500093 | 0.61% | 股份 |
| Simplify Asset Management Inc. | $5720629 | 400044 | 0.49% | 股份 |
| Ikarian Capital, LLC | $5296720 | 370400 | 0.46% | 买入期权 |
| Ikarian Capital, LLC | $5296720 | 370400 | 0.46% | 卖出期权 |
| Ghisallo Capital Management LLC | $5005000 | 350000 | 0.43% | 股份 |
| STEMPOINT CAPITAL LP | $4840135 | 338471 | 0.42% | 股份 |
| E Fund Management Co., Ltd. | $4730068 | 330774 | 0.41% | 股份 |
| Jump Financial, LLC | $4586825 | 320757 | 0.39% | 股份 |
| Bleichroeder LP | $4526165 | 316515 | 0.39% | 股份 |
| Woodline Partners LP | $4296621 | 300463 | 0.37% | 股份 |
| Eversept Partners, LP | $4257610 | 297735 | 0.37% | 股份 |
| GOLDMAN SACHS GROUP INC | $4086797 | 285790 | 0.35% | 股份 |
| Rock Springs Capital Management LP | $3839822 | 268519 | 0.33% | 股份 |
| CITIGROUP INC | $3750032 | 262240 | 0.32% | 股份 |
| MYDA Advisors LLC | $3575000 | 250000 | 0.31% | 股份 |
| AXA Investment Managers S.A. | $3480640 | 244427 | 0.30% | 股份 |
| UBS Group AG | $3373442 | 235905 | 0.29% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $3342639 | 233751 | 0.29% | 股份 |
| Schonfeld Strategic Advisors LLC | $3285853 | 229780 | 0.28% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3038750 | 212500 | 0.26% | 卖出期权 |
| Propel Bio Management, LLC | $2741954 | 191745 | 0.24% | 股份 |
| Qube Research & Technologies Ltd | $2704159 | 189102 | 0.23% | 股份 |
| Walleye Capital LLC | $2691560 | 188221 | 0.23% | 股份 |
| Susquehanna Portfolio Strategies, LLC | $2685554 | 187801 | 0.23% | 股份 |
| BlackRock, Inc. | $2649890 | 185307 | 0.23% | 股份 |
| CITADEL ADVISORS LLC | $2559700 | 179000 | 0.22% | 卖出期权 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $2389303 | 169334 | 0.21% | 股份 |
| HighVista Strategies LLC | $2226567 | 155704 | 0.19% | 股份 |
| Granahan Investment Management, LLC | $2136234 | 149387 | 0.18% | 股份 |
| Swiss National Bank | $2034890 | 142300 | 0.17% | 股份 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1998711 | 139770 | 0.17% | 股份 |
| PANAGORA ASSET MANAGEMENT INC | $1890660 | 132214 | 0.16% | 股份 |
| Corient Private Wealth LP | $1827526 | 127799 | 0.16% | 股份 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $1740081 | 121684 | 0.15% | 股份 |
| BOOTHBAY FUND MANAGEMENT, LLC | $1548690 | 108300 | 0.13% | 买入期权 |
| BOOTHBAY FUND MANAGEMENT, LLC | $1548690 | 108300 | 0.13% | 卖出期权 |
| DIADEMA PARTNERS LP | $1520090 | 106300 | 0.13% | 买入期权 |
| SILVERBACK ASSET MANAGEMENT LLC | $1430000 | 100000 | 0.12% | 买入期权 |
| Squarepoint Ops LLC | $1401429 | 98002 | 0.12% | 股份 |
| RHUMBLINE ADVISERS | $1393341 | 97437 | 0.12% | 股份 |
| CITADEL ADVISORS LLC | $1357070 | 94900 | 0.12% | 买入期权 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1354752 | 105101 | 0.12% | 股份 |
| ALGERT GLOBAL LLC | $1129557 | 78990 | 0.10% | 股份 |
| Waverly Advisors, LLC | $1114170 | 77914 | 0.10% | 股份 |
| Cinctive Capital Management LP | $1037923 | 72582 | 0.09% | 股份 |
| Caption Management, LLC | $1036750 | 72500 | 0.09% | 买入期权 |
| WELLINGTON MANAGEMENT GROUP LLP | $1035134 | 72387 | 0.09% | 股份 |
| GOLDMAN SACHS GROUP INC | $1002430 | 70100 | 0.09% | 买入期权 |
| DEUTSCHE BANK AG\ | $989860 | 69221 | 0.09% | 股份 |
| Bank of New York Mellon Corp | $981824 | 68659 | 0.08% | 股份 |
| WOODSTOCK CORP | $979049 | 68465 | 0.08% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $971081 | 75336 | 0.08% | 股份 |
| BANK OF AMERICA CORP /DE/ | $930186 | 65048 | 0.08% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $865708 | 60539 | 0.07% | 股份 |
| FOX RUN MANAGEMENT, L.L.C. | $836950 | 58528 | 0.07% | 股份 |
| Y-Intercept (Hong Kong) Ltd | $732017 | 51190 | 0.06% | 股份 |
| SILVERBACK ASSET MANAGEMENT LLC | $715000 | 50000 | 0.06% | 股份 |
| JANE STREET GROUP, LLC | $715000 | 50000 | 0.06% | 买入期权 |
| Erste Asset Management GmbH | $705500 | 50000 | 0.06% | 股份 |
| VANGUARD ASSET MANAGEMENT, Ltd | $702545 | 49129 | 0.06% | 股份 |
| Point72 Asset Management, L.P. | $694608 | 48574 | 0.06% | 股份 |
| SBI Okasan Asset Management Co.Ltd. | $644827 | 45700 | 0.06% | 股份 |
| MetLife Investment Management, LLC | $621607 | 43469 | 0.05% | 股份 |
| JANE STREET GROUP, LLC | $597954 | 41815 | 0.05% | 股份 |
| SCOTIA CAPITAL INC. | $597039 | 41751 | 0.05% | 股份 |
公司内部人士 25 位内幕人士 · 12 位高管 · 16 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Jay S. Duker | President and CEO | 2026年7月10日 M | 9594 | 0 | 0 | $0 |
| Nancy Lurker | President & CEO | 2018年10月12日 A | 211700 | 0 | 0 | $0 |
| Paul Ashton | President & CEO | 2016年3月18日 M | 450741 | 0 | 0 | $0 |
| David Price | Chief Financial Officer | 2018年8月1日 A | — | 0 | 0 | $0 |
| Michael Soja | VP Finance, CFO & Treasurer | 2008年9月10日 A | — | 0 | 0 | $0 |
| Ramiro Ribeiro | Chief Medical Officer | 2026年6月30日 M | 0 | 0 | 2 | $-73174 |
| Leonard S Ross | Vice President of Finance and Chief Accounting Officer | 2018年12月22日 M | 76187 | 0 | 0 | $0 |
| Dario A. Paggiarino | Chief Medical Officer | 2018年10月12日 F | 29600 | 0 | 0 | $0 |
| Leonard M Blum | Executive VP and General Manager, US | 2018年5月14日 A | — | 0 | 0 | $0 |
| Debora Jorn | EVP, Corp. & Comm'l Dev. | 2017年6月27日 A | — | 0 | 0 | $0 |
| Lori Freedman | VP Corporate Affairs, General Counsel and Secretary | 2016年7月21日 A | 96423 | 0 | 0 | $0 |
| Aaron Finlay | Secretary | 2007年10月18日 A | — | 0 | 0 | $0 |
| Karen L. Zaderej | 董事 | 2026年8月18日 P | 49100 | 1 | 0 | $52258 |
| Wendy F Dicicco | 董事 | 2026年1月2日 A | — | 0 | 0 | $0 |
| ANDO GORAN | 董事 | 2026年1月2日 A | — | 0 | 0 | $0 |
| Fred Hassan | 董事 | 2026年1月2日 A | — | 0 | 0 | $0 |
| Michael W Rogers | 董事 | 2018年11月15日 M | 112500 | 0 | 0 | $0 |
| John B. Landis | 董事 | 2018年10月25日 A | — | 0 | 0 | $0 |
| David J Mazzo | 董事 | 2018年9月6日 A | 138000 | 0 | 0 | $0 |
| Douglas Evan Godshall | 董事 | 2018年6月27日 M | 12500 | 0 | 0 | $0 |
| James J Barry | 董事 | 2018年5月7日 M | 12500 | 0 | 0 | $0 |
| Kristine Peterson | 董事 | 2017年12月15日 A | — | 0 | 0 | $0 |
| SAVAS PETER G | 董事 | 2015年12月3日 A | — | 0 | 0 | $0 |
| Paul Hopper | 董事 | 2013年12月18日 A | 10000 | 0 | 0 | $0 |
| Katherine Woodthorpe | 董事 | 2007年11月27日 A | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
激进投资者及 5%+ 股东 5 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| EW Healthcare Partners L.P., EW Healthcare Partners-A L.P., Essex Woodlands Fund IX-GP, L.P., Essex Woodlands IX, LLC, Martin P. Sutter, R. Scott Barry, Ronald Eastman, Petri Vainio, Steve Wiggins ×4 申报 | 2023年12月8日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2023年8月30日 | — | 初始申报 | — | SEC |
| Ocumension Therapeutics | 2021年1月22日 | — | 初始申报 | — | SEC |
| IRS Identification Nos. of above persons (entities only) Pfizer Inc. ×2 申报 | 2017年5月26日 | — | 初始申报 | — | SEC |
| Pfizer Inc. | 2007年7月17日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 42 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1.18% | 11564 NS | 2026年4月30日 | N-PORT |
| BBC · ETFis Series Trust I | 0.61% | 17260 NS | 2026年4月30日 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.12% | 25180 NS | 2026年5月31日 | N-PORT |
| NUSC · Nushares ETF Trust | 0.08% | 78250 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 0.06% | 3062 NS | 2026年5月31日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.04% | 25575 NS | 2026年5月31日 | N-PORT |
| RSSL · Global X Funds | 0.03% | 33518 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.03% | 3648 NS | 2026年5月31日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.02% | 378469 NS | 2026年5月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 34174 NS | 2026年4月30日 | N-PORT |
| UWM · ProShares Trust | 0.02% | 2853 NS | 2026年5月31日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.01% | 152391 NS | 2026年4月30日 | N-PORT |
| URTY · ProShares Trust | 0.01% | 2885 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.01% | 2895 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.00% | 72 NS | 2026年5月31日 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.00% | 28026 NS | 2026年5月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 3564 NS | 2026年4月30日 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 46188 NS | 2026年5月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 10667 NS | 2026年4月30日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 41879 NS | 2026年4月30日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 13282 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | — | — | 2026年7月15日 | 每日 |
| VFMO · VANGUARD WELLINGTON FUND | — | — | 2026年7月30日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 2026年7月15日 | 每日 |
| ITOT · iShares Trust | — | — | 2026年7月22日 | 每日 |
| IWV · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWN · iShares Trust | — | — | 2026年8月17日 | 每日 |
| IWO · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWM · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IWC · iShares Trust | — | — | 2026年8月18日 | 每日 |
| IHE · iShares Trust | — | — | 2026年8月18日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 2026年7月13日 | 每日 |
| VHT · VANGUARD WORLD FUND | — | — | 2026年7月20日 | 每日 |
| ISCB · iShares Trust | — | — | 2026年7月20日 | 每日 |
| ISCV · iShares Trust | — | — | 2026年7月20日 | 每日 |
| WSML · iShares Trust | — | — | 2026年7月20日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | — | — | 2026年7月20日 | 每日 |
| QQQS · Invesco Exchange-Traded Fund Trus... | — | — | 2026年8月5日 | 每日 |